504565943 09/26/2017

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT4612654

SUBMISSION TYPE:		NEW ASSIGNMENT			
NATURE OF CONVEYANCE:			ASSIGNMENT		
CONVEYING PARTY	DATA				
			Name	Execution Da	
LARS GUELEN				09/15/2017	
RECEIVING PARTY	DATA				
Name:	ADUR	ADURO BIOTECH EUROPE B.V.			
Street Address:	KLOO	KLOOSTERSTRAAT 9			
City:	OSS	OSS			
State/Country:	NETH	NETHERLANDS			
Postal Code:	5349 A	5349 AB			
PROPERTY NUMBE	RS Total: 1				
Property Type			Number		
Application Number: 1		15714	4585		
CORRESPONDENCE Fax Number:	E DATA	(732)5	594-4720		
		o the e	e-mail address first; if that is uns at is unsuccessful, it will be sen		
			594-5455		
Email:			s@merck.com		
Correspondent Nam	e:	MERC			
Address Line 1:			AST LINCOLN AVENUE		
Address Line 2:			6-2011A WAY, NEW JERSEY 07065-0907		
			-		
ATTORNEY DOCKET NUMBER:			23413		
NAME OF SUBMITTER:			LI SU		
	SIGNATURE:		/Li Su, Reg. # 45,141/		
SIGNATURE: DATE SIGNED:			09/26/2017		
SIGNATURE:			09/26/2017		
SIGNATURE: DATE SIGNED:		iotech	-executed#page1.tif		

WORLDWIDE ASSIGNMENT

WHEREAS, I/WE,

(1) Lars Guelen , located at <u>Nijmegen, Netherlands</u>,

(hereinafter ASSIGNOR(S)), together with <u>Amy M. Beebe</u>, located at <u>Half Moon Bay, CA</u>, <u>Jason Ka Jen Cheung</u>, located at <u>Westfield</u>, NJ, <u>Veronica Juan</u>, located at <u>Redwood City, CA</u>, <u>Laurence Fayadat-Dilman</u>, located at <u>Sunnyvale</u>, <u>CA</u>, <u>Svetlana Sadekova</u>, located at <u>Mountain View, CA</u>, <u>Jerelyn Wong</u>, located at <u>San Jose, CA</u>, <u>Thierry</u> <u>Olivier Fischmann</u>, located at <u>Scotch Plains, NJ, Winifred W. Prosise</u>, located at <u>Ramsey, NJ</u>, <u>Hans van Eenennaam</u>, located at <u>Nijmegen</u>, <u>Netherlands</u> and <u>Andrea van Elsas</u>, located at <u>Oss</u>, <u>Netherlands</u>, are inventors of the invention described in an application for Patents having the Attorney Docket Number indicated above and the following Title of the Invention:

ANTI-CD27 ANTIBODIES

and in the following application(s):

U.S. Provisional Application No. <u>62/399,837</u> filed on <u>09/26/2016</u>; U.S. Provisional Application No. <u>62/546,214</u> filed on <u>08/16/2017</u>, U.S. Application No. . <u>15/714,585</u> having a filing date of . <u>09/25/2017</u>; and PCT International Application No. <u>PCT/US1753204</u> having a filing date of <u>09/25/2017</u>.

WHEREAS I/WE covenant that the rights and property herein conveyed are free and clear of any encumbrance, and that I/we have the full right to convey the same as herein expressed.

WHEREAS, Aduro Biotech Europe B.V., an entity residing under the laws of Netherlands, having an office at Kloosterstraat 9, 5349 AB, Oss, Netherlands, and its successors, assigns and legal representatives (hereinafter **ASSIGNEE**), is desirous of obtaining the entire right, title and interest in, to and under the invention disclosed in said application or applications;

NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, I/we, said ASSIGNOR(S), do each hereby sell, assign and transfer or confirm the grant and assignment to said ASSIGNEE my/our entire right, title and interest in all countries of the world in and to my/our invention described in said application for Patents, in and to the right to file patent applications in the name of ASSIGNEE, its designee, or in any or all of our names, at its election, on the aforesaid invention in all countries of the world, together with all rights of priority in the aforesaid countries deriving from the above-identified application for Patents under the International Convention for the Protection of Industrial Property, under the Inter-American Convention relating to Inventions, Patents, Designs and Industrial Models and under any other international arrangement relating to patents or intellectual property, in and to any and all Letters Patent that are granted from the aforesaid application for Patents, in and to any applications, divisions, reexaminations, reissues, renewals and extensions thereof of any of said Letters Patent, the same to be held and enjoyed by said ASSIGNEE, to the full ends of the terms for which all Letters Patent therefore may be granted, as fully and entirely as the same would have been held and enjoyed by us if this assignment and sale had not been made.

AND I/WE HEREBY covenant and agree that we will at any time, upon the request and at the expense of **ASSIGNEE**, without further compensation or charge to said **ASSIGNEE**, execute and deliver any and all documents that may be necessary or desirable to perfect the title to the foregoing invention, patent applications, and Letters Patent and continuations, divisions, reexaminations, reissues, renewals and extensions thereof in the name of **ASSIGNEE**, including the execution and procurement of any and all further documents evidencing this assignment and sale as may be necessary or desirable for recording the same in the Patent Office of any country concerned, and will make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein.

I/WE HEREBY authorize **ASSIGNEE** to insert in this instrument the Application Number(s) and the filing date(s) of said application for Patents when officially notified thereof.

This document may be executed in any number of counterparts, each of which so executed shall be deemed to be an original, but all such components shall together constitute but one and the same document.

Computer Generated Template "Assignment-Merck Sharp & Dohme. Multiple Assignees Worldwide" (Assignment) Merck Sharp & Dohme Corp. 07/09/2010

PATENT REEL: 043704 FRAME: 0125

Attorney Docket No.: 23413

ŝ

Worldwide Assignment

Executed this 5th day of <u>September 7</u>, 2017

Witness #1:

Edward de Cock [Witness #1 Print Neme]

Date: <u>15 Sp} 2017</u>

[Witness #1 Signature]

Witness #2:

Withess #2 Print Name)

[Witness #2 \$ignature]

..... Date: <u>15 San 2017</u>

Page 2 of 2 Assignment Merck Sharp & Dolme. Multiple Assigness Worldeide" (Assignment) Merck Sharp & Dolme Corp. 07/08/2010

RECORDED: 09/26/2017